203,100 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Purchased by Swiss National Bank

Swiss National Bank acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 203,100 shares of the company's stock, valued at approximately $1,218,000. Swiss National Bank owned 0.14% of Adaptive Biotechnologies at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Amundi increased its stake in shares of Adaptive Biotechnologies by 41.2% in the fourth quarter. Amundi now owns 15,532 shares of the company's stock worth $93,000 after acquiring an additional 4,531 shares during the last quarter. Arizona State Retirement System acquired a new position in Adaptive Biotechnologies in the 4th quarter worth about $179,000. Proficio Capital Partners LLC acquired a new position in Adaptive Biotechnologies in the 4th quarter worth about $93,000. Charles Schwab Investment Management Inc. raised its stake in shares of Adaptive Biotechnologies by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 956,574 shares of the company's stock worth $5,735,000 after purchasing an additional 39,831 shares in the last quarter. Finally, Versor Investments LP acquired a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $147,000. Hedge funds and other institutional investors own 99.17% of the company's stock.

Insiders Place Their Bets

In related news, Director Robert Hershberg sold 53,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $7.59, for a total value of $402,270.00. Following the completion of the sale, the director now owns 69,690 shares in the company, valued at approximately $528,947.10. This trade represents a 43.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Chad M. Robins sold 158,921 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $8.46, for a total value of $1,344,471.66. Following the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,798,890.46. This represents a 5.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 757,601 shares of company stock worth $6,040,624 in the last ninety days. Insiders own 6.20% of the company's stock.

Remove Ads

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded up $0.42 during trading hours on Wednesday, hitting $7.94. 2,183,070 shares of the company's stock were exchanged, compared to its average volume of 1,483,008. The company's 50-day moving average price is $7.91 and its 200-day moving average price is $6.43. Adaptive Biotechnologies Co. has a 1-year low of $2.28 and a 1-year high of $9.01. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -7.28 and a beta of 1.53.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. During the same quarter last year, the firm earned ($0.30) earnings per share. On average, research analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ADPT shares. Piper Sandler restated an "overweight" rating and issued a $11.00 price objective (up previously from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday, February 20th. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $8.00 to $9.00 in a report on Friday, March 21st. Finally, Scotiabank increased their target price on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $9.40.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.